DMAAU Kronos AI forecast
A 30-trading-day price forecast for Drugs Made In America Acquisition Corp. Units (DMAAU) from Kronos AI, an open-source foundation model trained on candlestick charts.
Kronos AI's median forecast puts Drugs Made In America Acquisition Corp. Units at $10.92 on 2026-12-07, −0.8% from the last close of $11.01 on 2026-10-26. Eight out of ten sampled paths end between $10.79 and $10.98, and 0 of the 8 paths finish above today's price.
Forecast path
median, with the 10–90% band of the sampled pathsOpen the interactive forecast → Full analysis of DMAAU
The forecast, week by week
| Date | Median | Low (10%) | High (90%) |
|---|---|---|---|
| 2026-11-02 | $10.95 | $10.91 | $11.01 |
| 2026-11-09 | $10.99 | $10.91 | $11.02 |
| 2026-11-16 | $10.99 | $10.95 | $11.20 |
| 2026-11-23 | $10.97 | $10.75 | $11.10 |
| 2026-11-30 | $10.94 | $10.81 | $11.06 |
| 2026-12-07 | $10.92 | $10.79 | $10.98 |
What is Kronos AI?
Kronos is an open-source foundation model for financial candlesticks, pre-trained on K-line data from more than 45 exchanges. Gnzub runs it on each stock's last 120 daily bars and samples several possible futures, so the forecast is a range of outcomes rather than one confident line. It is a statistical model, not an analyst: it reads price patterns only and knows nothing about news, earnings or the business.
Questions
- What is the Kronos AI forecast for DMAAU?
- Kronos AI's median forecast for DMAAU is $10.92 in 30 trading days, −0.8% from the last close, with a 10–90% range of $10.79 to $10.98.
- Is the DMAAU Kronos forecast a buy or sell signal?
- No. It is the output of a statistical model that reads price history only. It is not investment advice, and the range shows how uncertain the model is.
- How often is the forecast updated?
- The forecasts are regenerated regularly; this one starts from the close of 2026-10-26.
Kronos forecasts for similar companies
- TACO — Berto Acquisition Corp.
- PRE — Prenetics Global Limited
- OXSQ — Oxford Square Capital Corp.
- ILLU — Illumination Acquisition Corp I
- INV — Innventure Inc.
- MLEC — Moolec Science SA